鼻腔给药
卵清蛋白
粘膜免疫
免疫学
TLR9型
免疫系统
鼻粘膜
CpG寡核苷酸
免疫
抗体
抗原
医学
生物
基因表达
DNA甲基化
基因
生物化学
作者
Yuchun Xu,Xiaoying Winston Yan,Ting Wei,Minming Chen,Jiafei Zhu,Juxin Gao,Bo Liu,Wenjun Zhu,Zhuang Liu
出处
期刊:Nano Letters
[American Chemical Society]
日期:2023-11-09
卷期号:23 (22): 10522-10531
被引量:32
标识
DOI:10.1021/acs.nanolett.3c03419
摘要
Intranasal vaccines can induce protective immune responses at the mucosa surface entrance, preventing the invasion of respiratory pathogens. However, the nasal barrier remains a major challenge in the development of intranasal vaccines. Herein, a transmucosal nanovaccine based on cationic fluorocarbon modified chitosan (FCS) is developed to induce mucosal immunity. In our system, FCS can self-assemble with the model antigen ovalbumin and TLR9 agonist CpG, effectively promoting the maturation and cross-presentation of dendritic cells. More importantly, it can enhance the production of secretory immunoglobin A (sIgA) at mucosal surfaces for those intranasally vaccinated mice, which in the meantime showed effective production of immunoglobulin G (IgG) systemically. As a proof-of-concept study, such a mucosal vaccine inhibits ovalbumin-expressing B16-OVA melanoma, especially its lung metastases. Our work presents a unique intranasal delivery system to deliver antigen across mucosal epithelia and promote mucosal and systemic immunity.
科研通智能强力驱动
Strongly Powered by AbleSci AI